| scholarly article | Q13442814 |
| P50 | author | Simon F Lacey | Q56978267 |
| Bruce L. Levine | Q85544154 | ||
| Carl H. June | Q19277113 | ||
| P2093 | author name string | Stephen J Schuster | |
| J Joseph Melenhorst | |||
| Elise A Chong | |||
| Vanessa Gonzalez | |||
| David E Ambrose | |||
| P2860 | cites work | Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells | Q39122553 |
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Q41429394 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1039-1041 | |
| P577 | publication date | 2016-12-28 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. | |
| P478 | volume | 129 |
| Q50028516 | A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells |
| Q92436831 | A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model |
| Q93039755 | Advances and Challenges of CAR T Cells in Clinical Trials |
| Q38666304 | An Update on the Use of Immunotherapy in the Treatment of Lymphoma |
| Q45871879 | Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. |
| Q93088931 | Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma |
| Q92376089 | Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade |
| Q48507616 | Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice |
| Q99712199 | Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv |
| Q89457607 | B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models |
| Q64075193 | Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing |
| Q90677062 | CAR T Cell Therapy Progress and Challenges for Solid Tumors |
| Q60047537 | CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success |
| Q45868734 | CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma |
| Q64235860 | CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment |
| Q64891859 | CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q92325228 | CAR T cells take centre stage |
| Q96306695 | CAR T-cell immunotherapy of B-cell malignancy: the story so far |
| Q97067646 | CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape |
| Q47285613 | CAR-T cells and combination therapies: What's next in the immunotherapy revolution? |
| Q64250623 | CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy |
| Q39246685 | CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond |
| Q55477963 | CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. |
| Q55193924 | CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. |
| Q93133450 | CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors |
| Q90484164 | Cell-Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen-Presenting Cells for T Cell Activation |
| Q64055595 | Challenges of driving CD30-directed CAR-T cells to the clinic |
| Q100455153 | Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas |
| Q58594803 | Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma |
| Q89532702 | Checkpoint inhibitor immunotherapy in kidney cancer |
| Q64246214 | Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies |
| Q38685785 | Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. |
| Q94526312 | Chimeric antigen receptor T cell therapy comes to clinical practice |
| Q38600697 | Chimeric antigen receptor T-cell therapies for lymphoma |
| Q64270990 | Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges |
| Q55443158 | Chimeric antigen receptor T‑cell therapy—a hematological success story. |
| Q64267591 | Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma |
| Q64105309 | Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells |
| Q101476341 | Counteracting CAR T cell dysfunction |
| Q61453759 | Current development of chimeric antigen receptor T-cell therapy |
| Q39280002 | Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment |
| Q39200527 | Development of CAR T cells designed to improve antitumor efficacy and safety |
| Q47681393 | Discovery and application of immune biomarkers for hematological malignancies. |
| Q88884600 | Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication |
| Q89032225 | Driving cars to the clinic for solid tumors |
| Q64227219 | Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis |
| Q90334543 | Emerging Cellular Therapies for Cancer |
| Q68691940 | Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56 |
| Q49962991 | Engineering chimeric antigen receptor-T cells for cancer treatment |
| Q92236859 | Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date |
| Q90618258 | Gene editing and CRISPR in the clinic: current and future perspectives |
| Q67201058 | Gene editing for immune cell therapies |
| Q89815118 | Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes |
| Q64252172 | Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer |
| Q90862859 | Genetically engineered T cells for cancer immunotherapy |
| Q98181408 | IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors |
| Q92470683 | Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled |
| Q57168423 | Immunological-based approaches for cancer therapy |
| Q90474093 | Immunomodulators in Lymphoma |
| Q48525241 | Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. |
| Q91240562 | L’émergence des traitements par cellules CAR-T dans les lymphomes |
| Q89896175 | Monitoring Immune Responses in Neuroblastoma Patients during Therapy |
| Q95642943 | Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer |
| Q97420808 | Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients |
| Q90482989 | Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade |
| Q92480852 | PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity |
| Q54965277 | Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. |
| Q88886221 | Pitfalls of Combining Novel Agents in Lymphoma |
| Q90215603 | Programming CAR-T cells to kill cancer |
| Q50026306 | Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer |
| Q94545391 | Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward |
| Q93023571 | Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma |
| Q98292027 | Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease |
| Q47157402 | Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. |
| Q52597541 | Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. |
| Q56891950 | Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma |
| Q92959947 | Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation |
| Q97646320 | Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways |
| Q64066845 | Switching on the green light for chimeric antigen receptor T-cell therapy |
| Q98771256 | Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q92592749 | T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study |
| Q53123844 | Targeting Immune System Alterations in Hodgkin Lymphoma. |
| Q58561607 | Teaching an old dog new tricks: next-generation CAR T cells |
| Q54985631 | The Pharmacology of T Cell Therapies. |
| Q39130457 | The Principles of Engineering Immune Cells to Treat Cancer |
| Q64990793 | The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome. |
| Q89515386 | The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 |
| Q47590707 | The progress and current status of immunotherapy in acute myeloid leukemia |
| Q59339934 | The role of neoantigen in immune checkpoint blockade therapy |
| Q40199809 | Therapeutic T cell engineering |
| Q57476217 | Tim-3 expression and its role in hepatocellular carcinoma |
| Q39448180 | Treating breast cancer with cell-based approaches: an overview. |
| Q52780137 | Trial Watch: Adoptively transferred cells for anticancer immunotherapy. |
| Q97568608 | Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma |
| Q94453577 | Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy |
| Q58122378 | [Efficacy and safety of reduced dose of PD-1 inhibitor combined with CD19-CAR-T on B-cell non-Hodgkin lymphoma patients with high expression of PD-1 in peripheral blood] |
Search more.